NeuBase Therapeutics, Inc. (NBSE)

NASDAQ: NBSE · IEX Real-Time Price · USD
0.378
-0.006 (-1.56%)
May 10, 2024, 12:00 AM EDT - Market open
Market Cap 1.42M
Revenue (ttm) n/a
Net Income (ttm) -13.73M
Shares Out 3.75M
EPS (ttm) -7.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 97,744
Open 0.381
Previous Close 0.384
Day's Range 0.378 - 0.378
52-Week Range 0.360 - 4.440
Beta 0.95
Analysts n/a
Price Target n/a
Earnings Date Aug 12, 2024

About NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Todd P. Branning
Employees 37
Stock Exchange NASDAQ
Ticker Symbol NBSE
Full Company Profile

Financial Performance

Financial Statements

News

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from the L...

3 months ago - GlobeNewsWire

NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder

PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S...

11 months ago - GlobeNewsWire

SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE

URGES BOARD TO CONSIDER A $1 DIVIDEND TORONTO , Sept. 6, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in N...

11 months ago - PRNewsWire

NeuBase Therapeutics to Explore Strategic Alternatives

PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc.  (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editi...

1 year ago - GlobeNewsWire

NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

PITTSBURGH, June 30, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editin...

1 year ago - GlobeNewsWire

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing

PITTSBURGH, June 29, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editin...

1 year ago - GlobeNewsWire

NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

PITTSBURGH, June 28, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editin...

1 year ago - GlobeNewsWire

NeuBase Announces 1-for-20 Reverse Stock Split

PITTSBURGH, June 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc.  (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editi...

1 year ago - GlobeNewsWire

NeuBase to Participate in Jefferies Healthcare Conference

PITTSBURGH, May 24, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing...

1 year ago - GlobeNewsWire

NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™

PITTSBURGH, May 22, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing...

1 year ago - GlobeNewsWire

NeuBase Announces Formation of Gene Editing Advisory Board

Appointed Jeffrey Kindler, J.D. and John Maraganore, Ph.D. as strategy and business advisors to the Company Appointed Jeffrey Kindler, J.D. and John Maraganore, Ph.D. as strategy and business advisors...

1 year ago - GlobeNewsWire

NeuBase Reports Business Update and Financial Results for the First Quarter of 2023

Announced oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting to take place on May 16-20, 2023

1 year ago - GlobeNewsWire

NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting

PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing...

1 year ago - GlobeNewsWire

NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023

PITTSBURGH, Feb. 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the ba...

1 year ago - GlobeNewsWire

NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022

PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the ba...

1 year ago - GlobeNewsWire

NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company

PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the ba...

1 year ago - GlobeNewsWire

NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing

PITTSBURGH, Oct. 14, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today announced plans to restructure the Company to focus on the advancement of its...

1 year ago - GlobeNewsWire

NeuBase to Participate at Chardan's 6th Annual Genetic Medicines Conference

PITTSBURGH and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to add...

1 year ago - GlobeNewsWire

NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022

PITTSBURGH and CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to addr...

2 years ago - GlobeNewsWire

NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO

PITTSBURGH and CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to addr...

2 years ago - GlobeNewsWire

NeuBase to Participate at the Jefferies Healthcare Conference

PITTSBURGH and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to addr...

2 years ago - GlobeNewsWire

NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022

PITTSBURGH and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to addre...

2 years ago - GlobeNewsWire

NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

PITTSBURGH and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to addre...

2 years ago - GlobeNewsWire

NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal

PITTSBURGH and CAMBRIDGE, Mass., March 13, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to add...

2 years ago - GlobeNewsWire

NeuBase to Present at Oppenheimer's 32nd Annual Healthcare Conference

PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to add...

2 years ago - GlobeNewsWire